Koshinski Asset Management Has Lifted Cvs Health (CVS) Stake By $688,350; 5 Analysts Covering Charles River Laboratories Intl. (CRL)

June 19, 2017 - By Vivian Park

Among 11 analysts covering Charles River Laboratories (NYSE:CRL), 5 have Buy rating, 1 Sell and 5 Hold. Therefore 45% are positive. Charles River Laboratories had 22 analyst reports since August 3, 2015 according to SRatingsIntel. On Friday, August 28 the stock rating was maintained by William Blair with “Outperform”. The firm has “Sell” rating by UBS given on Tuesday, September 6. As per Friday, May 20, the company rating was maintained by Barclays Capital. Robert W. Baird maintained the shares of CRL in report on Friday, January 8 with “Outperform” rating. The rating was maintained by Jefferies with “Buy” on Thursday, August 4. The firm earned “Neutral” rating on Tuesday, June 21 by Credit Suisse. Jefferies maintained Charles River Laboratories Intl. Inc (NYSE:CRL) rating on Monday, April 24. Jefferies has “Buy” rating and $106 target. The firm has “Neutral” rating given on Thursday, August 4 by Citigroup. The rating was upgraded by Goldman Sachs to “Neutral” on Friday, December 16. The stock has “Outperform” rating by Wells Fargo on Thursday, January 7. See Charles River Laboratories Intl. Inc (NYSE:CRL) latest ratings:

24/04/2017 Broker: Jefferies Rating: Buy New Target: $106.00 Maintain
04/01/2017 Broker: Evercore Old Rating: Hold New Rating: Buy Upgrade

Koshinski Asset Management Inc increased Cvs Health Corp (CVS) stake by 293.09% reported in 2016Q4 SEC filing. Koshinski Asset Management Inc acquired 8,825 shares as Cvs Health Corp (CVS)’s stock declined 4.23%. The Koshinski Asset Management Inc holds 11,836 shares with $933,000 value, up from 3,011 last quarter. Cvs Health Corp now has $75.54B valuation. The stock decreased 3.78% or $3.03 during the last trading session, reaching $77.06. About 7 shares traded. CVS Health Corp (NYSE:CVS) has declined 24.40% since June 19, 2016 and is downtrending. It has underperformed by 41.10% the S&P500.

The stock increased 0.64% or $0.61 on June 16, reaching $95.76. About shares traded. Charles River Laboratories Intl. Inc (NYSE:CRL) has risen 7.06% since June 19, 2016 and is uptrending. It has underperformed by 9.64% the S&P500.

Charles River Laboratories International, Inc. is an early-stage contract research company. The company has market cap of $4.59 billion. The Firm is engaged in laboratory animal medicine and science and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. It has a 28.13 P/E ratio. The Firm operates in three divisions: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Investors sentiment increased to 1.11 in 2016 Q4. Its up 0.16, from 0.95 in 2016Q3. It improved, as 27 investors sold Charles River Laboratories Intl. Inc shares while 98 reduced holdings. 37 funds opened positions while 102 raised stakes. 44.60 million shares or 0.46% less from 44.81 million shares in 2016Q3 were reported. Fiera Cap holds 146,780 shares. Redmile Grp Llc stated it has 1.62% of its portfolio in Charles River Laboratories Intl. Inc (NYSE:CRL). Aristotle Capital Boston Ltd Limited Liability Company owns 64,702 shares for 0.68% of their portfolio. Janus Mgmt Limited Liability holds 0% of its portfolio in Charles River Laboratories Intl. Inc (NYSE:CRL) for 75,600 shares. Ibm Retirement Fund reported 3,719 shares stake. Globeflex Capital L P invested in 0.77% or 40,610 shares. First Mercantile Trust stated it has 0.08% in Charles River Laboratories Intl. Inc (NYSE:CRL). First Quadrant L P Ca has invested 0.08% in Charles River Laboratories Intl. Inc (NYSE:CRL). Invesco Limited reported 490,588 shares. Whittier Co holds 0% or 1,150 shares. Teachers Retirement Systems Of The State Of Kentucky holds 11,500 shares. Blackrock Lc invested 0% in Charles River Laboratories Intl. Inc (NYSE:CRL). Sei accumulated 0.04% or 96,799 shares. 56,500 were reported by Pdt Prtn Ltd Liability Co. Aperio Grp Limited holds 22,177 shares.

Since January 30, 2017, it had 0 insider purchases, and 18 sales for $9.43 million activity. FOSTER JAMES C also sold $300,300 worth of Charles River Laboratories Intl. Inc (NYSE:CRL) on Wednesday, February 22. 6,735 shares were sold by BERTOLINI ROBERT J, worth $592,702. On Friday, May 12 the insider Kochevar Deborah Turner sold $26,408. 945 Charles River Laboratories Intl. Inc (NYSE:CRL) shares with value of $89,775 were sold by Smith David Ross. Barbo William D also sold $1.10M worth of Charles River Laboratories Intl. Inc (NYSE:CRL) shares. $286,254 worth of Charles River Laboratories Intl. Inc (NYSE:CRL) was sold by Molho Davide on Friday, March 10. JOHST DAVID P sold $653,540 worth of stock.

Investors sentiment decreased to 0.74 in Q4 2016. Its down 0.24, from 0.98 in 2016Q3. It dived, as 135 investors sold CVS shares while 627 reduced holdings. 127 funds opened positions while 440 raised stakes. 830.51 million shares or 0.72% less from 836.58 million shares in 2016Q3 were reported. Culbertson A N & stated it has 107,869 shares or 2.9% of all its holdings. Thompson Siegel And Walmsley Limited accumulated 34,839 shares. First Mercantile Trust Company invested 0% of its portfolio in CVS Health Corp (NYSE:CVS). The Minnesota-based Foundry Partners Limited Liability Company has invested 0.39% in CVS Health Corp (NYSE:CVS). 607 are held by Arcadia Invest Mngmt Mi. St Johns Invest Limited Liability, a Florida-based fund reported 11,448 shares. Davidson And Garrard Incorporated owns 104,756 shares. Fic Cap has invested 0.42% of its portfolio in CVS Health Corp (NYSE:CVS). Investment Mngmt Of Virginia Limited reported 23,409 shares. Stralem & Co reported 2.56% of its portfolio in CVS Health Corp (NYSE:CVS). Dreman Value Management L L C invested in 0.36% or 8,061 shares. Cetera accumulated 15,240 shares or 0.09% of the stock. Greenwood Gearhart accumulated 27,882 shares. Truepoint holds 0.37% in CVS Health Corp (NYSE:CVS) or 43,414 shares. Armstrong Shaw Assoc Inc Ct stated it has 155,887 shares.

Since February 1, 2017, it had 0 buys, and 7 insider sales for $40.53 million activity. The insider Denton David M sold $18.44M. $4.90M worth of stock was sold by Roberts Jonathan C on Thursday, February 16. Boratto Eva C had sold 6,029 shares worth $479,908. $1.88 million worth of CVS Health Corp (NYSE:CVS) shares were sold by Brennan Troyen A. On Monday, March 13 Sussman Andrew sold $1.13 million worth of CVS Health Corp (NYSE:CVS) or 14,104 shares. 76,494 shares were sold by MERLO LARRY J, worth $5.99 million on Wednesday, February 1.

Koshinski Asset Management Inc decreased Jetblue Airways Corp (NASDAQ:JBLU) stake by 23,937 shares to 15,480 valued at $849,000 in 2016Q4. It also reduced Amazon Com Inc (NASDAQ:AMZN) stake by 425 shares and now owns 214 shares. Ishares Tr (IYH) was reduced too.

Among 17 analysts covering CVS Health (NYSE:CVS), 10 have Buy rating, 0 Sell and 7 Hold. Therefore 59% are positive. CVS Health had 27 analyst reports since July 22, 2015 according to SRatingsIntel. As per Wednesday, November 9, the company rating was maintained by Mizuho. The firm earned “Outperform” rating on Friday, August 28 by Oppenheimer. Robert W. Baird downgraded CVS Health Corp (NYSE:CVS) rating on Thursday, February 2. Robert W. Baird has “Neutral” rating and $77 target. Jefferies maintained CVS Health Corp (NYSE:CVS) rating on Thursday, May 12. Jefferies has “Buy” rating and $122 target. RBC Capital Markets maintained the shares of CVS in report on Wednesday, August 5 with “Outperform” rating. The firm earned “Neutral” rating on Thursday, December 17 by Goldman Sachs. The rating was initiated by Tigress Financial with “Buy” on Friday, April 28. Citigroup maintained the shares of CVS in report on Monday, May 9 with “Neutral” rating. The stock has “Hold” rating by Jefferies on Monday, December 12. Argus Research maintained the stock with “Buy” rating in Monday, August 10 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: